Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management.

Laredo, Viviana; García-Mateo, Sandra; Martínez-Domínguez, Samuel J; López de la Cruz, Julia; Gargallo-Puyuelo, Carla J; Gomollón, Fernando

Laredo, Viviana; García-Mateo, Sandra; Martínez-Domínguez, Samuel J; López de la Cruz, Julia; Gargallo-Puyuelo, Carla J; Gomollón, Fernando.

Afiliación

Laredo V; Department of Gastroenterology, Lozano Blesa University Hospital, 50009 Zaragoza, Spain.
García-Mateo S; Aragón Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain.
Martínez-Domínguez SJ; School of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
López de la Cruz J; Department of Gastroenterology, Lozano Blesa University Hospital, 50009 Zaragoza, Spain.
Gargallo-Puyuelo CJ; Aragón Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain.
Gomollón F; School of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.

Cancers (Basel) ; 15(3)2023 Jan 31.

Article en En | MEDLINE | ID: mdl-36765829

Palabras clave

Inflammatory Bowel Disease; biologic therapy; cancer; immunosuppressive drugs; tofacitinib; treatment decisions

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google